Founded in 1996, GBS invests in young businesses developing and commercialising products which, when combined with the right management and finance, will make a significant difference to patients' lives and deliver financial returns for their investors. Their areas of particular interest and expertise include human healthcare, biotechnology product development and life science start-ups. In particular, recent investments have included biological or small molecule therapeutics, medical devices and diagnostics.

GBS invests in private or public companies whether at start-up or later stages of company development. Their investors include major Australian superannuation funds.

GBS Venture Partners

Investment Manager

Partner

Co-Founder and Managing Partner

Investment Professional

Investment Director

Ocunexus Therapeutics raised $19200000 on 2011-04-18 in Series B

Ocunexus Therapeutics is a biopharmaceutical company that develops therapeutics for unmet clinical needs in ophthalmology. The company specializes in developing highly differentiated drug candidates based upon a novel mechanism of action called “Gap Junction Channel Modulation.”  It has developed treatments for multiple front- and back-of-the-eye diseases and disorders that would potentially alter the standard of care. In addition, the company's technologies are expected to be transferable to other acute and chronic disease indications.

Ocunexus is formerly known as CoDa Therapeutics, a pharmaceutical company focused on the development and commercialization of wound care therapeutics based on gap junction modulation. The company is based in San Diego, California.

CoDa Therapeutics

Euthymics Bioscience raised $24000000 on 2010-07-22 in Series A

Euthymics Bioscience, Inc., a neuroscience-focused-clinical-stage biopharmaceutical company, that develops therapeutics, which help patients with withdrawal symptoms, impulsivity, and cravings. It develops a medicine for alcohol use disorder and smoking cessation. Euthymics Bioscience, Inc. was founded in 2009 and is based in Cambridge, Massachusetts.

Euthymics Bioscience, Inc.

Spinifex Pharmaceuticals raised $45000000 on 2014-04-10 in Series C

Spinifex is backed by a syndicate of experienced life science investors including Novo Ventures, Canaan Partners, GBS Venture Partners, Brandon Capital Partners, Uniseed and UniQuest. Founded in 2005, Spinifex raised an initial AU$3.25 million in Series A fundraising and a total of AU$23.08 in Series B funding support the further development of EMA401. Spinifex raised a US$45 million in a Series C round led by Novo Ventures and including additional new investor Canaan Partners in 2014.

Spinifex has a strong portfolio of intellectual property around its lead compound EMA01, follow on candidates and the use of AT2 receptor antagonists to treat both neuropathic & inflammatory pain and restore nerve conduction velocity deficits, including granted US, European, Japanese, Chinese, Australian and New Zealand patents.

Spinifex Pharmaceuticals

Hatchtech raised $8100000 on 2012-05-01 in Venture Round

Hatchtech is an Australian company developing a locally developed proprietary technology platform that will enable the creation of a new generation of lowtoxicity pest control products. Specifically, the patented technology allows the complete blocking of pest species egg hatch through a novel mode of action. The technology has applicability for controlling ectoparasites and other egg laying pests of humans, animal, crops and the built environment.

Hatchtech

Moximed raised $10000000 on 2022-01-01 in Venture Round

Moximed, Inc. develops a joint preserving option for patients with knee osteoarthritis. The company offers Atlas System, an implantable joint unloader that works like a shock absorber for a patient with medial compartment knee osteoarthritis, or suffering from pain on the medial (inner) side of the knee, or desire to maintain high activity or productivity levels. It serves patients and medical professionals worldwide. Moximed, Inc. was formerly known as ExploraMed NC4, Inc. The company was incorporated in 2006 and is based in Hayward, California.

Moximed

AirXpanders raised $9000000 on 2013-06-03 in Series E

AirXpanders develop technology enabling tissue expansion after reconstructive surgery with an emphasis on breast reconstruction. It addresses current unmet needs for patients who require tissue expansion after reconstructive surgery with the first emphasis on breast reconstruction. Present methods of tissue expansion utilize saline-filled implants that are typically injected on a weekly basis after surgery in order to reach the volume of skin and tissue required for the placement of a permanent breast implant.

AirXpanders, Inc.

OPAL Therapeutics raised $6000000 on 2005-10-31 in Series A

OPAL Therapeutics Pty Limited operates as an immunotherapy development company in Australia. It develops therapies for the treatment of human immunodeficiency virus, Hepatitis C, and chronic infection. OPAL Therapeutics Pty Limited was incorporated in 2005 and is based in Melbourne, Australia.

OPAL Therapeutics

AirXpanders raised $3000000 on 2011-03-02 in Series C

Xenome raised $6000000 on 2008-07-24 in Venture Round

Xenome is a progressive Australian biotechnology company with a promising and distinctive technology platform targeting pain and inflammation.  Xen2174, the Company's lead drug candidate is currently completing a Phase 1b/2a clinical trial for cancer pain with evidence to date providing strong support that the trial endpoints will be successfully met.  More substantive clinical trials for expanded indications are planned for 2008.  In addition, the drug discovery platform from which Xen2174 emerged has inherent value due to its ability to repeatedly identify new lead medicinal compounds on the basis of its unique construction around Australian biodiversity.  Specifically, Xenome has generated a unique expertise in peptide chemistry to translate the evolutionary advantages inherent in venom peptides into highly bioactive libraries of molecules that are of interest to global biotechnology and pharmaceutical companies.

Xenome

Nuon Therapeutics raised $5000000 on 2007-07-20 in Series A

Nuon Therapeutics is focused on the development and commercialization of new therapies in inflammation and neurological diseases, including rheumatoid arthritis (RA), multiple sclerosis (MS) and neuropathic pain.

Nuon Therapeutics

Phenomix raised $55000000 on 2007-03-08 in Series C

As of October 2010, Phenomix closed down as it was unable to find a partner to pay for is clinical trial bills after Forest Laboratories walked away. 

Phenomix is a drug discovery and development company building a portfolio of novel therapeutics for the treatment of major human diseases. Phenomix' lead clinical candidate, PHX1149, is a DPP4 inhibitor in phase 2 testing as a once daily oral treatment for type 2 diabetes. Phenomix' second program is directed at the treatment of hepatitis C through inhibition of the NS3/4A viral protease. Phenomix is based in San Diego, California.

Phenomix

AirXpanders raised $10308000 on 2012-01-23 in Series D

AIMEDICS raised $2040000 on 2010-08-27 in Venture Round

Aidmedics is a medical devices company that develops a device that identifies night-time hypoglycaemia to alert patients & care takers.

It offers The HypoMon, an alarm system that identifies night-time hypos in children and young adults aged between 10 and 25 years with type 1 diabetes. It serves care takers, clients, and health professionals in the United States, Europe, Australia, and New Zealand. AIMEDICS Pty Ltd was founded in 2001 and is based in Eveleigh, Australia with an additional office in Warwick, United Kingdom.

AIMEDICS

Moximed raised $40000000 on 2022-08-16 in Series C

Hydrexia raised $9250000 on 2013-06-01 in Series B

Hydrexia is an Australian company that has successfully designed, built, and tested systems that stores hydrogen in solid form, based on a proprietary magnesium alloy.

Hydrexia

Moximed raised $12617182 on 2016-01-27 in Series B

Viveve raised $4000000 on 2010-04-29 in Venture Round

Viveve is a women's sexual health company that develops non-surgical treatment for women's sexual health. It focuses on developing a Viveve procedure, a non-surgical treatment for women who have experienced vaginal looseness and loss of physical sensation that is common to women after vaginal childbirth. The company’s Viveve System is a radiofrequency device that uses low levels of energy to restore collagen fibers overstretched and damaged during vaginal childbirth. 

Viveve, Inc. was formerly known as TiVaMed, Inc. and changed its name to Viveve, Inc. in November 2009. The company was founded in 2005 and is based in Palo Alto, California.

Viveve

Hatchtech raised $2200000 on 2005-05-30 in Venture Round

NovaSys raised $49500000 on 2008-05-16 in Venture Round

At NovaSys Health they value your participation as a contracted provider. Roughly 11,000 providers in this region and over 4,300 providers in Arkansas have contracted with NovaSys Health making it one of the largest health plans in Arkansas. They take pride in the relationships that they have cultivated with providers.

NovaSys

Pathway Therapeutics raised $9600000 on 2008-06-18 in Series A

Pathway Therapeutics is focused on the discovery and development of best in class isoform selective inhibitors of PI3-kinase (PI3K) for the treatment of cancer and inflammatory diseases in targeted patient populations most likely to benefit.

Pathway Therapeutics

Neurovance raised $7000000 on 2012-10-18 in Venture Round

Neurovance, Inc., a neuroscience-focused company, focuses on the development and commercialization of therapies for adult and children with attention deficit hyperactivity disorders. The company develops centanafadine, a triple reuptake inhibitor that modulates the activity of norepinephrine dopamine and serotonin in a specific ratio. Neurovance, Inc. was incorporated in 2011 and is headquartered in Cambridge, Massachusetts. As of March 31, 2017, Neurovance, Inc. operates as a subsidiary of Otsuka America, Inc..

Neurovance

ChemGenex Pharmaceuticals raised $16437313 on 2007-03-04 in Series A

ChemGenex Pharmaceuticals Ltd, an integrated biopharmaceutical development company, engages in the discovery and the development of oncology drugs. The company's product candidates include omacetaxine mepesuccinate, an investigational small molecule agent that is in Phase 2/3 clinical trial for the treatment of chronic myelogenous leukemia, and is also in Phase 2 clinical trials for the treatment of acute myelogenous leukemia and myelodysplastic syndrome; and Quinamed, which is in Phase 2 clinical trial for the treatment of hormone refractory prostate cancer. It was formerly known as AGT Biosciences Limited and changed its name to ChemGenex Pharmaceuticals Ltd in June 2004. The company was founded in 1958 and is headquartered in Geelong, Australia.

ChemGenex Pharmaceuticals

NOVASYS MEDICAL raised $49500000 on 2008-05-15 in Series D

$25 million in Series C preferred stock financing. The financing will be used to ramp up operations and prepare for sales and marketing in anticipation of the company commercializing its first product, the Novasys Micro-remodeling™ System. The system, which is designed to treat female stress urinary incontinence (SUI), has received the CE Mark for use in the European Union and is pending FDA marketing clearance for sale in the United States. Novasys Medical Inc is testing a new, non-incisional, transurethral treatment which requires no visualization of the treatment site (neither cystoscopy nor fluoroscopy), being guided by familiar balloon palpation (similar to a Foley catheter). In addition, the Novasys Micro-remodeling™ System incorporates numerous, automatic safety features making the treatment process very easy to learn and use. The treatment does not require general anesthesia and is performed in the outpatient or office setting. Not only is the treatment rapid (less than 10 minutes), but patients immediately return to virtually all activities. As there are no incisions, no wound care or dressing changes are required.

NOVASYS MEDICAL

Hatchtech raised $6300000 on 2010-10-26 in Venture Round

Pathway Therapeutics raised $2400000 on 2009-10-09 in Series A

Proacta raised $7000000 on 2006-09-11 in Series A

Proacta Inc. is a private, clinical-stage, biopharmaceutical company headquartered in San Diego, California. They are focused on addressing unmet needs in the field of cancer with the development of hypoxia-activated prodrugs that target cancer cells.

Proacta was founded on intellectual property generated in New Zealand at the University of Auckland and in the United States at Stanford University.

Proacta's patent family covers a series of hypoxia-activated prodrugs designed to treat cancer. Expansion of this portfolio is supported by ongoing research at The University of Auckland.

PR610 is the lead compound from their pipeline of pro-drugs based on hypoxia-activated tyrosine-kinase inhibitors. These pro-drugs selectively release active tyrosine-kinase inhibitors within the low-oxygen (hypoxic) environment found in many solid tumors. By shifting the release of active drug away from normal tissues and into cancer tissues, these drugs are predicted to be more effective and less toxic than currently available therapies.

To date, Proacta has raised $43 million in two private financings. Investors include Alta Partners, Clarus Ventures, Delphi Ventures, Endeavour Capital (New Zealand), GBS Venture Partners (Australia), Genentech, No 8 Ventures (New Zealand) and Roche.

Proacta

AirXpanders raised $11000000 on 2012-04-20 in Series D

Peplin raised $24000000 on 2008-08-19 in Private Equity Round

Peplin is a development-stage specialty pharmaceutical company focused on advancing and commercializing medical dermatology products.


The Company is developing PEP005 (ingenol mebutate) (PEP005), which is derived from Euphorbia peplus (E. peplus), a plant referred to as petty spurge or radium weed. Peplin’s lead product candidate, which is in Phase III clinical trials, is a patient-applied topical gel containing PEP005, a compound used for the treatment of actinic keratosis (AK). Peplin’s other product candidate is a physician-applied topical gel for the treatment of superficial basal cell carcinoma (superficial BCC), PEP005 Gel for BCC. The active compound in each product is a small molecule extracted and purified from the sap of E. peplus.


On October 16, 2008, the Company acquired Neosil, Inc., a dermatology-focused company. Later on, Peplin, Inc. was acquired by LEO Pharma A/S.

Peplin

Euthymics Bioscience raised $4000000 on 2011-03-09 in Series A

NeuroVista raised $16500000 on 2010-08-18 in Venture Round

NeuroVista Corporation, a medical device company, develops medical technologies for the management and treatment of epilepsy in the United States. It offers advisory technologies to help mitigate the uncertainty of when epileptic seizures may strike. The company was formerly known as BioNeuronics Corporation and changed its name to NeuroVista Corporation in May 2007. NeuroVista Corporation was incorporated in 2002 and is based in Seattle, Washington.

NeuroVista

Ocunexus Therapeutics raised $20000000 on 2006-10-10 in Series A

Spinifex Pharmaceuticals raised $19000000 on 2011-08-23 in Series B

Xenome raised $10000000 on 2010-04-22 in Venture Round

Elastagen raised $9120842 on 2016-01-07 in Series B

Elastagen Pty Ltd., a clinical stage medical company, produces and sells products based on the human protein tropoelastin. The company offers injectable dermoaesthetic products, stretch mark products, scar revision and wound healing products, and sealant and osteoskeletal products for applications areas, including skin rejuvenation, scar remodeling, and tissue repair. It sells its products through online orders. Elastagen Pty Ltd. was founded in 2003 and is based in Eveleigh, Australia with production operations in Europe; and clinical operations in the United Kingdom. As of April 6, 2018, Elastagen Pty Ltd. operates as a subsidiary of Allergan plc.

Elastagen Pty Ltd.

Uptake Medical raised $9000000 on 2006-05-08 in Series A

Uptake Medical develops innovative medical technologies for the treatment of lung diseases. Its first product, InterVapor™, is the first and only approach to endoscopic lung volume reduction for people with severe emphysema that uses the body’s natural healing process without leaving any foreign materials in the lung. In clinical studies, InterVapor has demonstrated clinically meaningful improvements in breathing function, exercise capacity and quality of life.

Uptake Medical

Verva Pharmaceuticals raised $1599197 on 2009-06-18 in Venture Round

Verva Pharmaceuticals Ltd. (“Verva”) was formed in December, 2007 by consolidation of key diabetes assets, discovery technologies and targets resident in Autogen Research Ltd. (formerly the diabetes-focused subsidiary of ChemGenex Pharmaceuticals) with those of obesity drug development company Adipogen Pharmaceuticals Pty Ltd. The combined product portfolio, technologies and expertise provide a substantial opportunity for rapid clinical progress and growth in high-value markets with a significant unmet medical need.

Verva operates in a completely virtual mode, managed by a CEO and Directors with extensive international product development and partnering experience. Verva’s founding research was undertaken at the Metabolic Research Unit of Deakin University in Geelong, Australia; a state-of-the-art facility providing access to key in vitro and in vivo models and capabilities.  Verva has subsequently engaged expert scientists,  clinicians, technical advisers and contract research organisations worldwide to implement the Company’s research and development strategy.

Verva Pharmaceuticals

Proacta raised $1500000 on 2004-07-26 in Series A

Uptake Medical raised $17500000 on 2010-07-07 in Series B

Pathway Therapeutics raised $7500000 on 2011-05-25 in Series A

Humanigen raised $12000000 on 2008-12-22 in Series D

Humanigen is a biopharmaceutical company that uses its biologic capabilities and its proprietary platform technology to develop first-in-class human antibody therapeutics. It focuses on preventing the serious and potentially life-threatening side-effects associated with chimeric antigen receptor T-cell (CAR-T) therapy. Its pipeline includes programs such as Lenzilumab, Ifabotuzumab, and HGen005.

Humanigen, Inc.

Moximed raised $33000000 on 2015-05-07 in Series B

Uptake Medical raised $40259226 on 2012-03-13 in Series C

Ivantis raised $25000000 on 2014-09-23 in Series B

Ivantis, Inc. is a company focused on developing an innovative treatment for Glaucoma.  It is their goal to develop a less invasive, more effective option for the 60+ million people worldwide suffering from Primary Open Angle Glaucoma.  As they successfully address this initial goal, it is then there intention to focus on innovative development for the treatment of other debilitating diseases within ophthalmology.

Ivantis Inc.

Applied Physiology raised $5000000 on 2009-07-24 in Series B

Founded in 2004, Applied Physiology develops and commercializes treatment guidance systems intended to transform the care of critically-ill patients. The company's main focus is on real-time circulation management with its Navigator™ product. Applied Physiology has offices in Australia and the United Kingdom.

Applied Physiology

Humanigen raised $20000000 on 2005-03-16 in Series B

Ocunexus Therapeutics raised $20000000 on 2012-07-24 in Series B

Proacta raised $35000000 on 2007-02-07 in Series B

Neurovance raised $6300000 on 2014-04-03 in Series A

Humanigen raised $20000000 on 2008-09-23 in Series D

Pathway Therapeutics raised $4500000 on 2010-08-10 in Series A

AirXpanders raised $5400000 on 2010-04-29 in Series C

Spinifex Pharmaceuticals raised $2464056 on 2005-07-26 in Series A

Celladon raised $43000000 on 2012-02-15 in Venture Round

Celladon Corporation, a biotechnology company, develops and manufactures molecular therapies for the treatment of heart failure. Its products include SERCA2a, an enzyme that regulates calcium cycling and contractility in heart muscle cells; and MYDICAR, an enzyme replacement therapy for heart failure. Celladon was founded in 2000 and is based in La Jolla, California.

Celladon

CHF Solutions raised $9500000 on 2010-03-12 in Venture Round

CHF Solutions, Inc., a medical device company, focuses on developing, manufacturing, and commercializing devices used in ultrafiltration therapy. The company’s commercial product is the Aquadex FlexFlow System, which is indicated for temporary ultrafiltration treatment of patients with fluid overload who have failed diuretic therapy, and extended ultrafiltration treatment of patients with fluid overload who have failed diuretic therapy and require hospitalization. Its Aquadex FlexFlow system includes a console, disposable blood set, and catheter. The company sells its products to hospitals and clinics through its direct Salesforce in the United States; and through independent specialty distributors primarily in the United Kingdom, Italy, Spain, Germany, Austria, Switzerland, Southeast Asia, Brazil, India, and Greece. The company was formerly known as Sunshine Heart, Inc. and changed its name to CHF Solutions, Inc. in May 2017. CHF Solutions, Inc. was founded in 1999 and is headquartered in Eden Prairie, Minnesota.

CHF Solutions, Inc.

Phenomix raised $12000000 on 2002-03-11 in Series A

AirXpanders raised $1000000 on 2014-09-03 in Series E

Xenome raised $8067565 on 2011-12-21 in Venture Round

Nuon Therapeutics raised $10000000 on 2010-08-12 in Venture Round

Nuon Therapeutics raised $6050000 on 2010-03-17 in Venture Round

Moximed raised $50000000 on 2017-03-16 in Series C

NOVASYS MEDICAL raised $25000000 on 2004-04-30 in Series C

Ivantis raised $14000000 on 2014-01-13 in Series B